2/3 Institute of Medicine AIDS research panel have Conflicts of Interst – Assoc Press Thu, 17 Mar 2005 On Feb 25, the New York Times reported that 10 of 32 FDA panelists determining whether to recommend that COX 2 painkillers should allowed to be marketed despite the documented increased risk…
Pfizer Zoloft Warnings to Canadian Doctors Contrast to US – FDA Caves In to Pharma lobbying Thu, 10 Feb 2005 The FDA has, once again, quietly colluded with industry, compromising the safety of children’s lives to maintain drug manufacturers’ cash flow. After two FDA advisory committee hearings (Feb 2-3 and…
Efforts to promote Cymbalta for Fibromyalgia symptoms Wed, 20 Oct 2004 Cymbalta (duloxetine) was approved by the FDA as a treatment for depression in adults. No doubt in an effort to expand the drugs’ market, Eli Lilly tested the drug in patients with fibromyalgia. The published report claims women who…
Senator Says FDA Asked Canada NOT to Suspend Adderall, Drug used for ADHD – NYT Fri, 11 Feb 2005 The New York Times reports that not only has the FDA failed to act to protect children and adults from a drug that has been linked to about 20 sudden deaths,…
SEC Focusing on Drug Makers Disclosure_ Continuing Medical Ed Changes Tue, 28 Sep 2004 Evidence showing that drug manufacturers and the FDA concealed negative clinical trial data and deceived physicians, consumers, and shareholders about failure to demonstrate the safety and effectiveness of SSRI antidepressant drugs has caught the interest of…
Govt Prozac study Recommends MANDATORY Screening & Drugs – “Overdosed America”_OpEd NYT Sun, 19 Sep 2004 FDA’s Review of Safety & Efficacy Concerns in Anti-Depressant Use by Children is the subject of a second Congressional hearing by the House Energy & Commerce Subcommittee on Oversight / Investigations on September 23,…
18% decrease SSRI use in Youth – NYT / Suicide Risk Not New – Globe / Prozac no different Tue, 21 Sep 2004 The FDA failed to stop drug manufacturers from flooding the air waves and the scientific literature with false and scientifically invalid claims-based on partial data. “The FDA…
ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) www.ahrp.org ***PRESS STATEMENT*** Re: The FDA & Concealment of Suicide-Related Risks of Antidepressants Date: September 14, 2004 Contact: Vera Hassner Sharav, President We are witnessing the unraveling of a system that was intended to ensure that marketed drugs met high safety standards; that…
AHRP Press Briefing September 14, 2004 Antidepressants and Suicide-Related Risks for Children Scientists’ Presentations at AHRP Press Briefing in Conjunction with FDA Hearings: Peter Mansfield, MD, University of Adelaide (Australia), Director of Healthy Skepticism discussed the illusion of potency in light of the meta-analyses in the British Medical Journal (which…
We are witnessing the unraveling of a system that was intended to ensure that marketed drugs met high safety standards; that physicians were informed about potential, serious adverse drug effects – so that they would prescribe judiciously; and that the integrity of the scientific literature was preserved. But that system has been hijacked by the drug industry – which has infected medical practice and medical research with detail men and informercials that make false claims while manipulating partial data to conceal adverse drug effects.
FDA’s Waiting Game Exposes Children to Preventable Risks Comments by Vera Hassner Sharav President The Alliance for Human Research Protection Submitted to FDA Advisory Committee Psychopharmacological Drugs Advisory Committee and Pediatric Subcommittee Drugs Advisory Committee September 13-14, 2004 Meeting RE: Suicidality Associated with Antidepressant Drug Treatment The Alliance for Human…
